# Amtagvi® (lifileucel) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/lifileucel

> The FDA approved Amtagvi® (lifileucel), sponsored by IOVANCE BIOTHERAPEUTICS, INC. (IOVA), on February 16, 2024 for with post-anti-PD-1 advanced melanoma.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Amtagvi® (lifileucel) FDA approved?

Yes. The FDA approved Amtagvi® (lifileucel), sponsored by IOVANCE BIOTHERAPEUTICS, INC. (IOVA), on February 16, 2024 for with post-anti-PD-1 advanced melanoma. Press release filed with the SEC (EX-99): "The U.S. FDA approved Amtagvi (lifileucel) on February 16, 2024, as the first treatment option for patients with advanced (unresectable or metastatic) melanoma after anti-PD-1 and targeted therapy." [Calendar and source filings](https://sec-api.dev/pdufa/lifileucel)

Source: Press release filed with the SEC (EX-99), accession 0001104659-25-075175, https://www.sec.gov/Archives/edgar/data/1425205/000110465925075175/tm2522769d1_ex99-1.htm (retrieved 2026-11-12). Last confirmed 2025-11-06. Cite: https://sec-api.dev/pdufa/lifileucel#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Amtagvi® (lifileucel) |
| Codes | LN-144 |
| Sponsor | IOVANCE BIOTHERAPEUTICS, INC. (IOVA) https://sec-api.dev/companies/iova/catalysts |
| Indications | with post-anti-pd-1 advanced melanoma, advanced ups or ddlps, [advanced melanoma](https://sec-api.dev/indications/advanced-melanoma), advanced, [Endometrial Cancer](https://sec-api.dev/indications/endometrial-cancer), Melanoma (Skin Cancer) |
| Modality | cell_therapy |
| FDA designations | accelerated, breakthrough, fast track, orphan, priority review, rmat |

## Timeline

### May 2023: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2025-02-27, last confirmed 2025-11-06.
- SEC Form 10-Q (accession 0001104659-25-107470): "The FDA accepted our BLA for Amtagvi® for patients with advanced melanoma in May 2023 and granted lifileucel Priority Review." https://www.sec.gov/Archives/edgar/data/1425205/000110465925107470/iova-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-010807): "The FDA accepted our BLA for Amtagvi® for patients with advanced melanoma in May 2023 and granted lifileucel Priority Review." https://www.sec.gov/Archives/edgar/data/1425205/000155837025010807/iova-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007009): "The FDA accepted our BLA for Amtagvi® for patients with advanced melanoma in May 2023 and granted lifileucel Priority Review." https://www.sec.gov/Archives/edgar/data/1425205/000155837025007009/iova-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-001834): "The FDA accepted our BLA for Amtagvi® for patients with advanced melanoma in May 2023 and granted lifileucel Priority Review." https://www.sec.gov/Archives/edgar/data/1425205/000155837025001834/iova-20241231x10k.htm

### February 16, 2024: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: with post-anti-PD-1 advanced melanoma.
- First seen 2025-02-27, last confirmed 2025-11-06.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-075175): "The U.S. FDA approved Amtagvi (lifileucel) on February 16, 2024, as the first treatment option for patients with advanced (unresectable or metastatic) melanoma after anti-PD-1 and targeted therapy." https://www.sec.gov/Archives/edgar/data/1425205/000110465925075175/tm2522769d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-046101): "The U.S. FDA approved Amtagvi (lifileucel) on February 16, 2024, as the first treatment option for patients with advanced melanoma after anti-PD-1 and targeted therapy." https://www.sec.gov/Archives/edgar/data/1425205/000110465925046101/tm2514273d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-018212): "U.S. FDA approved Amtagvi (lifileucel) on February 16, 2024, as the first treatment option for patients with advanced melanoma after anti-PD-1 and targeted therapy." https://www.sec.gov/Archives/edgar/data/1425205/000110465925018212/tm257755d1_ex99-1.htm
- SEC Form 10-Q (accession 0001104659-25-107470): "Following U.S. FDA approval of Amtagvi® for the treatment of patients with post-anti-PD-1 advanced melanoma on February 16, 2024, our top priority is continuing to leverage our experienced marketing, payer access, and distribution teams, as well as a sales force with extensive experience in oncology and cell therapy for our commercialization efforts." https://www.sec.gov/Archives/edgar/data/1425205/000110465925107470/iova-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-010807): "Following U.S. FDA approval of Amtagvi® for the treatment of patients with post-anti-PD-1 advanced melanoma on February 16, 2024, our top priority is continuing to leverage our experienced marketing, payer access, and distribution teams, as well as a sales force with extensive experience in oncology and cell therapy for our commercialization efforts." https://www.sec.gov/Archives/edgar/data/1425205/000155837025010807/iova-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007009): "Following U.S. FDA approval of Amtagvi® for the treatment of patients with post-anti-PD-1 advanced melanoma on February 16, 2024, our top priority is continuing to leverage our experienced marketing, payer access, and distribution teams, as well as a sales force with extensive experience in oncology and cell therapy for our commercialization efforts." https://www.sec.gov/Archives/edgar/data/1425205/000155837025007009/iova-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-001834): "Following U.S. FDA approval of Amtagvi® for the treatment of patients with post-anti-PD-1 advanced melanoma on February 16, 2024, our top priority is continuing to leverage our experienced marketing, payer access, and distribution teams, as well as a sales force with extensive experience in oncology and cell therapy for our commercialization efforts." https://www.sec.gov/Archives/edgar/data/1425205/000155837025001834/iova-20241231x10k.htm

### February 24, 2024: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2025-02-27, last confirmed 2025-08-07.
- SEC Form 10-Q (accession 0001558370-25-010807): "The FDA originally assigned November 25, 2023 as the target action date for a decision under PDUFA, however, the FDA then reassigned February 24, 2024 as the revised target action date before approving the BLA on February 16, 2024." https://www.sec.gov/Archives/edgar/data/1425205/000155837025010807/iova-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007009): "The FDA originally assigned November 25, 2023 as the target action date for a decision under PDUFA, however, the FDA then reassigned February 24, 2024 as the revised target action date before approving the BLA on February 16, 2024." https://www.sec.gov/Archives/edgar/data/1425205/000155837025007009/iova-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-001834): "The FDA originally assigned November 25, 2023 as the target action date for a decision under PDUFA, however, the FDA then reassigned February 24, 2024 as the revised target action date before approving the BLA on February 16, 2024." https://www.sec.gov/Archives/edgar/data/1425205/000155837025001834/iova-20241231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-075175): "The U.S. FDA approved Amtagvi (lifileucel) on February 16, 2024, as the first treatment option for patients with advanced (unresectable or metastatic) melanoma after anti-PD-1 and targeted therapy." https://www.sec.gov/Archives/edgar/data/1425205/000110465925075175/tm2522769d1_ex99-1.htm

### Feb 2026: interim data readout

- Status: completed, positive. Date confidence: month. Indication: advanced UPS or DDLPS.
- First seen 2026-05-07, last confirmed 2026-11-05.
- SEC Form 10-Q (accession 0001193125-26-448809): "For example, in February 2026, we announced positive initial data from a pilot clinical trial led by MSKCC and supported by us of lifileucel in patients with advanced UPS or DDLPS who were refractory to at least one prior line of systemic therapy." https://www.sec.gov/Archives/edgar/data/1425205/000119312526448809/iova-20260930.htm
- SEC Form 10-Q (accession 0001104659-26-091716): "For example, in February 2026, we announced positive initial data from a pilot clinical trial led by MSKCC and supported by us of lifileucel in patients with advanced UPS or DDLPS who were refractory to at least one prior line of systemic therapy." https://www.sec.gov/Archives/edgar/data/1425205/000110465926091716/iova-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-056778): "For example, in February 2026, we announced positive initial data from a pilot clinical trial led by MSKCC and supported by us of lifileucel in patients with advanced UPS or DDLPS who were refractory to at least one prior line of systemic therapy." https://www.sec.gov/Archives/edgar/data/1425205/000110465926056778/iova-20260331x10q.htm

### Q2 2026: trial start

- Status: scheduled. Date confidence: quarter.
- First seen 2026-02-24, last confirmed 2026-05-07.
- SEC Form 10-Q (accession 0001104659-26-056778): "We are conducting registrational trials for advanced NSCLC and frontline advanced melanoma cancer with our lifileucel product candidate, and we plan to commence a registrational trial in previously treated advanced UPS and DDLPS in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1425205/000110465926056778/iova-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-018899): "We are conducting registrational trials for advanced NSCLC and frontline advanced melanoma cancer with our lifileucel product candidate, and we plan to commence a registrational trial in previously treated advanced UPS and DDLPS in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm

### 1H 2027: interim data readout

- Status: scheduled. Date confidence: half.
- First seen 2026-08-06, last confirmed 2026-08-06.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-091619): "Multiple patients have been treated for cutaneous squamous cell carcinoma (CSCC) and Merkel cell carcinoma (MCC) with initial data expected in 1H27." https://www.sec.gov/Archives/edgar/data/1425205/000110465926091619/tm2622322d1_ex99-1.htm

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Melanoma (Skin Cancer); Unresectable Melanoma; Metastatic Melanoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07288203 (A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Iovance Biotherapeutics, Inc.." https://clinicaltrials.gov/study/NCT07288203

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Melanoma (Skin Cancer); Unresectable Melanoma; Metastatic Melanoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07288203 (A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Iovance Biotherapeutics, Inc.." https://clinicaltrials.gov/study/NCT07288203

### May 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Endometrial Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06481592 (A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Iovance Biotherapeutics, Inc.." https://clinicaltrials.gov/study/NCT06481592

### May to Aug 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Endometrial Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06481592 (A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Iovance Biotherapeutics, Inc.." https://clinicaltrials.gov/study/NCT06481592

## Same indication

- [Bnt323/db-1303](https://sec-api.dev/pdufa/bnt323-db-1303) (BNTX)
- [Datopotamab deruxtecan (dato-dxd)](https://sec-api.dev/pdufa/datopotamab-deruxtecan-dato-dxd) (AZN)
- [Iscib1+](https://sec-api.dev/pdufa/iscib1) (SCNLD)
- [Opdivo® (nivolumab)](https://sec-api.dev/pdufa/nivolumab) (BMY)
- [Pemazyre (pemigatinib)](https://sec-api.dev/pdufa/pemigatinib) (INCY)
- [Puxitatug samrotecan](https://sec-api.dev/pdufa/puxitatug-samrotecan) (AZN)
- [Rina-s](https://sec-api.dev/pdufa/rina-s) (GMAB)
- [Sacituzumab govitecan-hziy](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) (GILD)
- [Sacituzumab tirumotecan](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) (MRK)
- [Sapanisertib](https://sec-api.dev/pdufa/sapanisertib) (FTH)
- [ENHERTU (trastuzumab deruxtecan)](https://sec-api.dev/pdufa/trastuzumab-deruxtecan) (AZN)
- [VS-7375](https://sec-api.dev/pdufa/vs-7375) (VSTM)
- [Vusolimogene oderparepvec](https://sec-api.dev/pdufa/vusolimogene-oderparepvec) (REPL)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/lifileucel.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Amtagvi® (lifileucel) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/lifileucel

```bibtex
@misc{secapidev_pdufa_lifileucel_20261116,
  title        = {Amtagvi® (lifileucel) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/lifileucel}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_lifileucel_20261116","title":"Amtagvi® (lifileucel) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/lifileucel","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
